[ET Net News Agency, 22 August 2019] Goldman Sachs raised its target price for Frontage
Holdings (01521) to HK$4.24 from HK$3.71 and maintained its "buy" rating.
The research house said Frontage's earnings of US$9.3mn were above Goldman's estimates
with one-off US tax benefits, while revenue of US$49.7mn was slightly below expectations,
with softer China operation due to capacity constraints for bioanalytical services and
ramp-up of new business (e.g., DMPK).
Goldman expects China revenue to accelerate in 2H 2019/2020 with ongoing capacity
expansion in Shanghai site. US sales accelerated, driven by enhanced capability in
capturing emerging demand for biologics/biomarker BA services and turnaround of Concord.
With US$87mn backlog by 1H, Goldman sees strong earnings' visibility over the next 12
months, with potential upside from expanding service offerings. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01521 FRONTAGE
Nominal 
1.250 -0.050 (-3.846%) Others
22/08/2019 17:54
{I-bank focus}Goldman raises Frontage (01521) to HK$4.24
| Remark: | Real time quote last updated: 24/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |